Merck target raised to $160 after Moderna cancer therapy data
Goldman Sachs raises its price target on Merck to $160 from $140 after partner mRNA cancer therapy data involving Moderna.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.